Study Title

pointbiopharma

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Study Details

Description:

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

Sponsor:

Point Biopharma

Government Study Link:

NCT04647526 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


John Cohchran VA St. Louis Health Care System

St. Louis, Missouri, United States


Greater Dayton Cancer Center

Kettering, Ohio, United States


University of Colorado Hospital

Aurora, Colorado, United States


Astera Cancer Care

East Brunswick, New Jersey, United States


Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States


University of Michigan Hospitals

Ann Arbor, Michigan, United States


Tri-State Urologic Services

Cincinnati, Ohio, United States


University of Kentucky Chandler Medical Center

Lexington, Kentucky, United States


VA Greater Los Angeles Healthcare System

Los Angeles, California, United States


Carolina Urologic Research Center

Myrtle Beach, South Carolina, United States


Tulane University Medical Center

New Orleans, Louisiana, United States


Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States


University of California Los Angeles, Nuclear Medicine Clinic

Los Angeles, California, United States


Stanford Cancer Institute

Stanford, California 94305, United States


Washington University School of Medicine

St. Louis, Missouri, United States


Karmanos Cancer Institute

Detroit, Michigan, United States


Excel Diagnostics & Nuclear Oncology Center

Houston, Texas, United States


University of Iowa Medical Center

Iowa City, Iowa, United States


H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, United States


Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States


Swedish Cancer Institute Research

Seattle, Washington, United States


University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, United States


University of Texas Southwestern Medical Centre

Dallas, Texas 75390, United States


New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center

Albuquerque, New Mexico, United States


Dallas VA Medical Center, Nuclear Medicine Service

Dallas, Texas, United States


Chesapeake Urology Associates (CUA) P.A.

Towson, Maryland, United States


Saint Louis University Hospital

St. Louis, Missouri, United States


Cedars-Sinai Medical Center

Los Angeles, California, United States


University of California Irvine Chao Family Comprehensive Cancer Center

Orange, California, United States


Canada

Jewish General Hospital

Montréal, Quebec, Canada


BC Cancer - Vancouver

Vancouver, British Columbia, Canada


Nova Scotia Health Authority

Halifax, Nova Scotia, Canada


London Health Sciences Center - Victoria Hospital

London, Ontario, Canada


CHUM - University Hospital of Montreal

Montréal, Quebec, Canada


Princess Margaret Cancer Centre

Toronto, Ontario, Canada


CHU of Quebec - Laval University

Québec, Quebec, Canada


Sunnybrook Research Institute, Odette Cancer Center

Toronto, Ontario, Canada


France

La Timone Hospital, Nuclear Medicine Department

Marseille, Bouches-du-Rhône, France


Center Jean Perrin, Department of Medical Oncology

Clermont-Ferrand, Puy-de-Dôme, France


Claude Huriez Hospital

Lille, Nord, France


Tenon Hospital, Department of Medical Oncology

Paris, France


Montpellier Cancer Institute, Department of Nuclear Medicine

Montpellier, Hérault, France


Netherlands

St. Antonius Hospital

Nieuwegein, Utrecht, Netherlands


Erasmus University Medical Center Rotterdam

3015 GD, Rotterdam, South Holland, Netherlands


Sweden

Sahlgrenska University Hospital

Göteborg, Västra Götaland, Sweden


Norrlands University Hospital, Department of Radiation Sciences, Oncology

Umeå, Västerbotten, Sweden


United Kingdom

Charing Cross Hospital, Department of Medical Oncology

Greater London, England, United Kingdom


Royal Marsden NHS Foundation Trust - Institute of Cancer Research

Sutton, Greater London, England, United Kingdom